"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 3 | 4 | 7 |
| 2005 | 1 | 5 | 6 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 3 | 8 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 3 | 5 |
| 2015 | 3 | 2 | 5 |
| 2016 | 6 | 2 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 2 | 3 |
| 2026 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
A retrospective analysis of the use of candesartan for migraine prevention in adolescents. Headache. 2024 01; 64(1):96-97.
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
-
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
-
Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach. Adv Protein Chem Struct Biol. 2023; 135:97-124.
-
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
-
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2020 06 09; 22(6):875-885.
-
Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol. 2020 04; 41(4):718-724.
-
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019 07; 20(7):1011-1022.
-
Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition. Pediatr Hematol Oncol. 2017 May; 34(4):254-259.